This activity is supported by educational grants from Celgene, Lilly, Sirtex, and Taiho Oncology, Inc.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Saturday, April 23, 2016
Grand Hyatt New York
New York, NY
There is a need for specialized education for clinicians who manage some of the most difficult-to-treat forms of gastrointestinal cancers. The School of Gastrointestinal Oncology™ (SOGO™) will provide a multi-module curriculum-based program focused exclusively on gastrointestinal tumors’ management. This intensive 1-day interactive program will provide a comprehensive review of data on the most important aspects related to the multidisciplinary management of gastrointestinal tumors. The program will focus on the latest data on prognostic and predictive markers that impact clinical decision-making, current and emerging treatment strategies, and case-based lectures by expert faculty whose will focus on the practical application of knowledge to the complex care scenarios encountered in contemporary practice settings.
This educational program is directed toward oncologists and gastroenterologists whose primary practice focus is gastrointestinal (GI) cancers and who intend to reinforce their knowledge base and expand their expertise in GI diagnosis, risk stratification, personalization of care, and best practices for multidisciplinary communication. Participants will be primarily oncologists, surgeons, gastroenterologists, interventional radiologists, radiation oncologists, fellows and other professionals who treat GI cancers whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of GI cancers.
At the conclusion of this activity, participants should be better prepared to:
March 8, 2018 - March 11, 2018
Miami Beach, FL
MBCC: A Better Way to Stop Pain: Experts Discuss Paths Toward Responsible Postsurgical Pain Management
March 8, 2018
March 10, 2018
SGO: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian Cancer
March 24, 2018
New Orleans, LA
Mar 31, 2018